Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)

Novartis Pharmaceuticals332 enrolled

Overview

The study evaluated the efficacy and safety of two different dosing regimens of ranibizumab (either monthly injections or injections as-needed based on the stability of a patient's vision) in Chinese patients with wet age-related macular degeneration (AMD) . This study was to provide long-term safety data in the treatment of Chinese patients with wet AMD.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

332

Conditions

Neovascular Age-related Macular Degeneration

Interventions

RanibizumabDRUG

Intravitreal injections of 0.5 mg Ranibizumab

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Key Inclusion criteria: * Patients with visual impairment due to neovascular AMD * A qualifying vision score at study entry Key Exclusion criteria * Active infection or inflammation either eye at study entry * Uncontrolled glaucoma in either eye * Any disorder in the study eye which may affect vision * Use of any systemic anti-vascular endothelial growth factor (VEGF)-drugs within 3 months prior to study entry * Previous treatment of the study eye for wet AMD * Any surgery in the study eye 3 months prior to or planned with 6 month after study entry

Locations (23)

Novartis Investigative Site

Beijing, Beijing Municipality, China

Outcomes

Primary Outcomes

Average Change in Visual Acuity (Letters) From Month 3 to Month 4 Through Month 12

Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like VA testing charts at a testing distance of 4 meters. This outcome measure describes the difference between the VA averaged across all visits from Month 4 through 12 and the Month 3 Level of Visual Acuity (Letters) of the Study Eye. The treatment regimen up to Month 3 is the same in both treatment groups.

Time frame: Month 3 to month 4 through Month 12

Secondary Outcomes

Average Visual Acuity Change (Letters) From Month 3 to Month 4 Through Month 24

Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes the difference between the average level of VA over all monthly post-baseline assessments from Month 4 to Month 24 and the Month 3 Level of VA. The treatment regimen up to Month 3 is the same in both treatment groups.

Time frame: Month 3 to month 4 through Month 24

Average Visual Acuity Change From Baseline to Month 1 Through Month 12 and Month 1 Through Month 24

Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes the difference between VA averaged across all visits from Month 1 through Month 12 (24) and the baseline VA level

Time frame: Baseline to Month 24

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Novartis Investigative Site

Beijing, Beijing Municipality, China

Novartis Investigative Site

Chongqing, Chongqing Municipality, China

Novartis Investigative Site

Lanzhou, Gansu, China

Novartis Investigative Site

Harbin, Heilongjiang, China

Novartis Investigative Site

Wuhan, Hubei, China

Novartis Investigative Site

Wuhan, Hubei, China

Novartis Investigative Site

Changsha, Hunan, China

Novartis Investigative Site

Nanjing, Jiangsu, China

Novartis Investigative Site

Nanchang, Jiangxi, China

...and 13 more locations

Change From Baseline in Visual Acuity (Letters) of the Study Eye Over Time

Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes the change in visual acuity at each visit compared to baseline

Time frame: Baseline to 24 months

Number of Patients With a BCVA Improvement of ≥5, ≥10, ≥15, and ≥30 Letters From Baseline to Month 24

Visual acuity (VA) was at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for each post-baseline month whether or not a patient improved by equal or more than 5, 10, 15,or 30 letters of VA as compared to baseline.

Time frame: Baseline to Month 24

Number of Patients With a BCVA Loss of 15 Letters in the Study Eye Over Time

Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for each post-baseline month whether or not a patient lost less than 15 letters of VA as compared with baseline.

Time frame: Baseline to Month 24

Number of Patients With a Best Corrected Visual Acuity (BCVA) of More of 73 Letters or More

Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for Month 12 and Month 24 whether a patient had a VA score of 73 or more letters

Time frame: Month 12 and 24

Change From Baseline in Central Sub-Field Thickness (CSFT) of the Study Eye Over Time to Month 12 and Month 24

Optical coherence tomography(OCT) was used to assess CSFT (Central Sub-Field Thickness) representing the average retinal thickness of the circular area within 1 mm diameter around the foveal center. The Ns in the rows is the number of patients with a value for both baseline and the specific post-baseline visit

Time frame: Baseline to Month 24

Duration of Ranibizumab Treatment Free Interval in the Study Eye up to Month 24

This outcome measure describes duration of treatment-free intervals. Treatment-free interval is defined as the number of visits (whether attended or not) where ranibizumab was not administered. n= the number of patients who had at least one ranibizumab treatment interruption

Time frame: up to month 24

Duration of Ranibizumab Treatment Free Interval in the Study Eye Prior to Month 12

This outcome measure describes duration of treatment-free intervals prior to month 12. Treatment-free interval is defined as the number of visits (whether attended or not) where ranibizumab was not administered. n= the number of patients who had at least one ranibizumab treatment interruption Treatment-free interval is analyzed in the Ranibizumab 0.5 mg PRN group only. It is not analyzed in the Ranibizumab 0.5 mg monthly group because, by protocol design, these participants receive treatment monthly. Therefore, the analysis does not apply to this group.

Time frame: prior to month 12

Duration of Active Treatment Phase Prior to Month 12

Time frame: Prior to month 12

Duration of Active Treatment Phase up to Month 24

Time frame: up to month 24